Gene Therapy

Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal and external bleeding episodes

Dr Reddy's Laboratories is looking to enhance its presence in various emerging segments like nutraceuticals and aims to get into integrated digital healthcare services as part of its future growth plans. In its Annual Report for 2022-23, the Hyderabad-based drug major informed the shareholders that it also intends to follow a disciplined approach towards cash management and acquisitions. "We are exploring business spaces that we think will shape the healthcare of the future. These include deepening our presence in nutraceuticals, cell and gene therapy and new chemical entities (NCEs)," Dr Reddy's Laboratories Chairman K Satish Reddy said. The drug firm is also exploring new spaces such as integrated digital healthcare services, digital therapeutics, and disease management, he added. "While these are long gestation businesses, and we are early in their development, we have made some progress," Reddy said. The drug firm informed the shareholders that it has a strategy in place which

Researchers at the University of Maryland School of Medicine (UMSOM) have discovered novel gene mutations responsible for a rare illness that causes heart failure in youngsters

The Indian Institute of Technology Kanpur on Friday said it has licensed a gene therapy technology that has the potential to treat many hereditary eye diseases to Reliance Life Sciences Pvt Ltd. The gene therapy technology from IIT Kanpur will be further developed as an indigenous product by Reliance Life Sciences. Developed by Jayandharan Giridhara Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), IIT Kanpur, the patented technology modifies the gene of an organism to treat a hereditary disorder, the institute said in a statement. "Gene therapy using viral vectors has recently emerged as a potent tool in the field of molecular medicine. "We believe that this technology holds great promise for treating a wide range of hereditary eye diseases including Leber congenital amaurosis, an eye disorder that is present from birth and Retinitis pigmentosa, a disease causing progressive sustained vision loss," IIT Kanpur Director Abhay Karandikar ...

CSL Behring's Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a key study of the therapy found

ImmunoACT, backed by Laurus Labs is testing their cancer product

Researchers used a genetic engineering strategy to reduce levels of tau--a key protein that accumulates and tangles in brain during the development of Alzheimer's--in an animal model of the condition

Putting aside prices for a moment, it's been an exciting period for medical progress

The Swiss drugmaker said last week that it was in the process of 'exiting' the Avexis scientists responsible for the manipulation of data on gene therapy Zolgensma

The approval of Spark Therapeutics Inc's Luxturna therapy would pave the way for new payment models for drugs, particularly in the US

The key to making the therapy work? One of medicine's greatest villains: HIV